Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 2/20 | 0.54 |
| ▸ | PDE4B | Q07343 | 5/20 | 0.49 |
| ▸ | TACR1 | P25103 | 3/20 | 0.47 |
| ▸ | STS | P08842 | 1/20 | 0.42 |
| ▸ | NAMPT | P43490 | 1/20 | 0.42 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.40 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.40 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.40 |
| ▸ | JAK2 | O60674 | 1/20 | 0.40 |
| ▸ | JAK1 | P23458 | 1/20 | 0.40 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4710969 | 0.90 | TACR1 (0.49) | RORCPDE4BTACR1STSGPR119 | |
| SCHEMBL20475142 | 0.88 | PDE4B (0.54) | RORCPDE4BSTSGPR119 | |
| SCHEMBL20475143 | 0.88 | PDE4B (0.54) | RORCPDE4BSTSGPR119 | |
| SCHEMBL23040383 | 0.88 | PDE4B (0.54) | RORCPDE4BSTSGPR119 | |
| SCHEMBL23040382 | 0.88 | PDE4B (0.54) | RORCPDE4BSTSGPR119 | |
| SCHEMBL4106856 | 0.86 | CCR5 (0.41) | — | |
| SCHEMBL4007683 | 0.83 | RORC (0.60) | RORCPDE4BTACR1NAMPTGPR119 | |
| SCHEMBL4390391 | 0.83 | RORC (0.60) | RORCPDE4BTACR1NAMPTGPR119 | |
| SCHEMBL4247036 | 0.83 | RORC (0.60) | RORCPDE4BTACR1NAMPTGPR119 | |
| SCHEMBL13809300 | 0.83 | RORC (0.60) | RORCPDE4BTACR1NAMPTGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1957450-B1 | SEROTONIN TRANSPORTER (SERT) INHIBITORS | HOFFMANN LA ROCHE (CH) | 2009-06-24 | — | — | EP | disclosed |
| EP-1957450-A1 | SEROTONIN TRANSPORTER (SERT) INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2008-08-20 | — | — | EP | disclosed |
| WO-2007063009-A1 | SEROTONIN TRANSPORTER (SERT) INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-06-07 | — | — | WO | disclosed |
| US-20070129419-A1 | Serotonin transporter (SERT) inhibitors for the treatment of depression and anxiety | HOFFMANN-LA ROCHE INC. | 2007-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070129419-A1 | Serotonin transporter (SERT) inhibitors for the treatment of depression and anxiety | SLC6A4, SLC6A2, SLC6A3 | RORC 3055/4885PDE4B 2554/4885TACR1 171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.